Charles Schwab’s PharmaCyte Biotech PMCB Stock Holding History

Charles Schwab’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,219	Closed	-$50.3K	–	3580
2022 Q4	$50.3K	Buy	+17,219	New	+$49.3K	﹤0.01%	3358

Other funds holding PMCB

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's PMCB Position: Q1 2023 in Review

Charles Schwab sold out of PharmaCyte Biotech (PMCB) in Q1 2023, closing a stake of 17,219 shares — an estimated $50.3K sold.

Charles Schwab first reported a position in PMCB in Q4 2022 and held it in 1 quarter. The position peaked at $50.3K in Q4 2022. 29 funds tracked by Wall St. Rank hold PMCB as of Q1 2023.

Charles Schwab reported no remaining PharmaCyte Biotech position as of Q1 2023 after selling out during the quarter.
Charles Schwab sold 17,219 PharmaCyte Biotech shares in Q1 2023, an estimated $50.3K.
Charles Schwab first reported a position in PharmaCyte Biotech in Q4 2022 and held it in 1 quarter.
Charles Schwab's PharmaCyte Biotech position peaked at $50.3K in Q4 2022.
29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.